MA48765A - Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub - Google Patents

Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Info

Publication number
MA48765A
MA48765A MA048765A MA48765A MA48765A MA 48765 A MA48765 A MA 48765A MA 048765 A MA048765 A MA 048765A MA 48765 A MA48765 A MA 48765A MA 48765 A MA48765 A MA 48765A
Authority
MA
Morocco
Prior art keywords
activity
sulfonamide substituted
dub inhibitors
cyanopyrrolidines
substituted cyanopyrrolidines
Prior art date
Application number
MA048765A
Other languages
English (en)
Inventor
Mark Ian Kemp
Andrew Madin
Martin Lee Stockley
Michael David Woodrow
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of MA48765A publication Critical patent/MA48765A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA048765A 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub MA48765A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1708652.1A GB201708652D0 (en) 2017-05-31 2017-05-31 Novel compounds and uses

Publications (1)

Publication Number Publication Date
MA48765A true MA48765A (fr) 2020-04-08

Family

ID=59270941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048765A MA48765A (fr) 2017-05-31 2018-05-30 Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub

Country Status (7)

Country Link
US (1) US11414402B2 (fr)
EP (1) EP3630096A1 (fr)
JP (1) JP7221217B2 (fr)
CN (1) CN110678176B (fr)
GB (1) GB201708652D0 (fr)
MA (1) MA48765A (fr)
WO (1) WO2018220355A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110831936B (zh) 2017-06-20 2023-03-28 特殊治疗有限公司 具有dub抑制剂活性的取代氰基吡咯烷
WO2019071073A1 (fr) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibition de la peptidase 30 spécifique de l'ubiquitine
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
AU2019356011B2 (en) 2018-10-05 2025-02-06 Forma Therapeutics, Inc. Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors
JP7734917B2 (ja) 2019-01-28 2025-09-08 ミトコンドリア エモーション, インク. トランス-4-ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション, インク. マイトフュージン活性化物質及びその使用方法
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
EP4157834B1 (fr) 2020-05-28 2024-07-03 Mission Therapeutics Limited Dérivés de n-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluorométhyl)phényl)oxazole-2-carboxamide et les dérivés de oxadiazole correspondants en tant qu'inhibiteurs d'usp30 pour le traitement de dysfonctionnement mitochondrial
IL298710A (en) 2020-06-04 2023-02-01 Mission Therapeutics Ltd N-cyanopyrrolidines with activity as USP30 inhibitors
KR20230022215A (ko) 2020-06-08 2023-02-14 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022159566A1 (fr) * 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzènesulfonamides comme agonistes de trap1 pour le traitement d'une fibrose d'organe
WO2023099561A1 (fr) 2021-12-01 2023-06-08 Mission Therapeutics Limited N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (fr) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Inhibiteurs de proteases a cysteine de type cathepsines
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
EP1948597A1 (fr) 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derives modulant des canaux ioniques
EP2152079A4 (fr) 2007-06-04 2011-03-09 Avila Therapeutics Inc Composés hétérocycliques et utilisations de ceux-ci
WO2009026197A1 (fr) * 2007-08-20 2009-02-26 Glaxo Group Limited Nouveaux inhibiteurs de la cathepsine c et leur utilisation
CL2009000915A1 (es) 2008-04-18 2010-04-16 Glaxo Group Ltd Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
WO2009129370A1 (fr) 2008-04-18 2009-10-22 Glaxo Group Limited Inhibiteurs de la cathepsine c
AR071369A1 (es) 2008-04-18 2010-06-16 Glaxo Group Ltd Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende
EP2565186A1 (fr) 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
CN103183673B (zh) 2011-12-30 2016-09-14 浙江新和成股份有限公司 (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法
PT3049417T (pt) 2013-07-31 2019-01-24 Merck Patent Gmbh Piridinas, pirimidinas e pirazinas, como inibidores de btk e utilizações das mesmas
WO2015179190A1 (fr) 2014-05-19 2015-11-26 Northeastern University Inhibiteurs d'amidase acide (naaa) hydrolysant la n-acyléthanolamine et leur utilisation
JP2017516801A (ja) 2014-05-27 2017-06-22 ファーマケア,インク. 脱ユビキチン化酵素阻害剤の組成物と送達の方法
WO2016019237A2 (fr) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
HRP20210791T2 (hr) 2015-03-30 2021-12-10 Mission Therapeutics Limited 1-cijano-pirolidin spojevi kao usp30 inhibitori
CN107849013B (zh) * 2015-07-14 2022-03-29 特殊治疗有限公司 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP3433246B1 (fr) 2016-03-24 2022-05-04 Mission Therapeutics Limited Dérivés de 1-cyano-pyrrolidine comme des inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110831936B (zh) 2017-06-20 2023-03-28 特殊治疗有限公司 具有dub抑制剂活性的取代氰基吡咯烷

Also Published As

Publication number Publication date
US11414402B2 (en) 2022-08-16
EP3630096A1 (fr) 2020-04-08
WO2018220355A1 (fr) 2018-12-06
JP7221217B2 (ja) 2023-02-13
JP2020521730A (ja) 2020-07-27
GB201708652D0 (en) 2017-07-12
US20200172518A1 (en) 2020-06-04
CN110678176B (zh) 2023-03-14
CN110678176A (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
EP3843714C0 (fr) Inhibiteurs de cd73
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
HUE057414T2 (hu) Új szulfonamid karboxamid vegyületek
MA52413A (fr) Inhibiteurs de cd73
IL269289A (en) Low-profile beam splitter
DK3612531T3 (da) Apoptose-inducerende midler
EP3549340A4 (fr) Mode de fusion multi-hypothèses
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EP3423435A4 (fr) Inhibiteurs d'indoles mcl-1 substitués
EP3787635A4 (fr) Inhibiteurs de cd73
EP3571523A4 (fr) Radar laser
IL252089B (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA49006A (fr) Inhibiteurs d'ip6k
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EP3418275A4 (fr) Nouveau composé thiophène substitué en 2,3,5 utilisé en tant qu'inhibiteur de la protéine kinase
EP4032455A4 (fr) Dispositif de nettoyage
EP3809933A4 (fr) Dispositif de nettoyage
EP3102571A4 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
EP3941635A4 (fr) Broyeur
EP3603610A4 (fr) Inhibiteur de l'activité de trpa1
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
EP3960060A4 (fr) Dispositif de nettoyage